New Delhi: Anthem Biosciences, a leading player in the biotechnology sector, made a striking debut on the stock market today, with its shares opening at ₹723.10 on the Bombay Stock Exchange (BSE) and ₹723.05 on the National Stock Exchange (NSE), resulting in a substantial listing gain of nearly 26% over its Initial Public Offering (IPO) price of ₹570. Despite initial gains, the stock experienced a slight pullback due to a selling trend, ultimately closing at ₹730.35 on the BSE, offering investors a solid return of approximately ₹160.35 per share — equating to a 28.13% profit on the debut day.
The IPO, which raised ₹3,395.79 crores, opened for subscription from July 14 to 16 and was met with overwhelming demand, being oversubscribed by a staggering 67.42 times overall. This level of interest highlights the confidence investors have in Anthem Biosciences, a company that specializes in providing biopharmaceutical research and development services.
The response from Qualified Institutional Buyers (QIBs) was particularly strong, with their portion of the offering being oversubscribed 192.80 times. Non-Institutional Investors (NIIs) also demonstrated high enthusiasm, subscribing to their portion 44.70 times, while retail investors showed steady interest with their portion being oversubscribed 5.98 times. Employee allocations saw a 6.99 times subscription rate, indicating robust participation across various investor categories.
Despite the IPO being oversubscribed, it’s important to note that Anthem Biosciences did not issue any new shares. Instead, it sold 5,95,75,319 shares with a face value of ₹2, offering existing shareholders the opportunity to monetize their investments. This share sale is a standard practice in IPOs where companies choose to offload a portion of their equity stake to raise funds, without diluting the ownership structure of the company.
Anthem Biosciences’ strong IPO debut is a reflection of the company’s solid financial track record and its growth potential in the rapidly expanding biotech sector. In its latest fiscal year (FY 2024-25), Anthem reported a net profit increase of 17.15%, rising from ₹385.19 crores in FY 2022-23 to ₹451.26 crores in FY 2024-25. The company’s revenue has also been growing at a robust Compound Annual Growth Rate (CAGR) of over 30%, reflecting its expanding presence in the biopharma industry and increasing demand for its services in drug development and related research.
The company’s management remains confident about maintaining its growth trajectory. Anthem’s specialized services in the biopharmaceutical domain, particularly in the areas of research and contract development, position it well for continued expansion. Given its established relationships with global pharmaceutical companies and its reputation for high-quality scientific solutions, Anthem Biosciences is poised to benefit from the growing global demand for innovative therapeutic solutions.
The biotechnology sector has seen impressive growth in recent years, driven by increasing global investments in healthcare, R&D, and personalized medicine. As pharmaceutical companies focus more on advanced therapies, contract research organizations (CROs) like Anthem Biosciences are likely to experience further growth. The company’s ability to provide cutting-edge research services and maintain a strong focus on emerging markets presents significant growth opportunities, which in turn fuels investor optimism.
This positive outlook, coupled with Anthem Biosciences’ healthy financial performance, has made it an attractive option for investors looking to capitalize on the growing demand for biotech services.
As the market reacts to Anthem’s debut, investors will closely monitor how the stock performs in the coming days. The early volatility observed on the debut day — where the price peaked at ₹746.70 before retracting slightly — is typical for newly listed stocks, but the strong listing gain indicates that investor sentiment remains bullish.
The company’s upcoming growth strategies, including potential expansions into new markets and further investments in R&D, are expected to be key drivers of its future performance. Additionally, any updates regarding strategic partnerships, product launches, or new innovations could further impact the stock’s trajectory.
